BE-SAFE: Deprescription of benzodiazepine and sedative hypnotics (BSHs) in insomnia disorder

Published by Thomas Agoritsas; Sumanth Kumbargere Nagraj; Enrico Callegari; Minna Johansson. on Dec 8, 2023

View

Disclaimer

Views and opinions expressed are however those of the author(s) only and do not necessarily reflect those of the European Union or of the SERI. Neither the European Union nor the SERI can be held responsible for them. 

Sponsors

This work is part of the project “BE-SAFE: Implementing a patient-centred and evidence-based intervention to reduce BEnzodiazepine and sedative-hypnotic use to improve patient SAFEty and quality of care” supported by the European Union's Horizon Europe research and innovation programme under the grantagreement No 101057123, and by the Swiss State Secretariat for Education, Research and Innovation (SERI) (contract No 22.00116).

Contact

Abstract

This guideline is one of the deliverables from BE-SAFE - Work Package 2 on “Clinical guidelines & implementation recommendations to reduce benzodiazepine and sedative hypnotics (BSHs) in patients diagnosed with insomnia disorder”

Language

en-gb

PICOS

PICO 10.1

Population
Patients using Benzodiazepines and closely related sedative hypnotics
Intervention
Education (Patients)
Comparator
Usual Care
Outcomes

PICO 20.1

Population
Patients using Benzodiazepines and closely related sedative hypnotics
Intervention
Education (Physicians)
Comparator
Usual Care
Outcomes

PICO 30.1

Population
Patients using benzodiazepines and closely related sedative hypnotics
Intervention
Interventions to help individual patients discontinue BSHs
Comparator
Usual Care
Outcomes

PICO 30.1

Population
Patients using Benzodiazepines and closely related sedative hypnotics
Intervention
Taper
Comparator
Usual Care
Outcomes

PICO 30.2

Population
Patients using benzodiazepines and closely related sedative hypnotics
Intervention
System level interventions
Comparator
Usual Care
Outcomes

PICO 30.2

Population
Patients using Benzodiazepines and closely related sedative hypnotics
Intervention
Cognitive Behavioural Therapy, Taper
Comparator
Cognitive Behavioural Therapy
Outcomes

PICO 40.1

Population
Patients using Benzodiazepines and closely related sedative hypnotics
Intervention
Multi-component
Comparator
Single-component
Outcomes

PICO 40.1

Population
Patients using Benzodiazepines and closely related sedative hypnotics
Intervention
Cognitive Behavioral Therapy
Comparator
Usual Care
Outcomes

PICO 40.2

Population
Patients using Benzodiazepines and closely related sedative hypnotics
Intervention
Multi-component Intervention
Comparator
Usual care
Outcomes

PICO 40.3

Population
Patients using Benzodiazepines and closely related sedative hypnotics
Intervention
Single-component Intervention
Comparator
Usual care
Outcomes

PICO 50.1

Population
Patients using Benzodiazepines and closely related sedative hypnotics
Intervention
Melatonin
Comparator
Taper
Outcomes

PICO 50.2

Population
Patients using Benzodiazepines and closely related sedative hypnotics
Intervention
Paroxetine
Comparator
Usual Care
Outcomes

PICO 50.3

Population
Patients using Benzodiazepines and closely related sedative hypnotics
Intervention
Paroxetine
Comparator
Taper
Outcomes

PICO 50.4

Population
Patients using Benzodiazepines and closely related sedative hypnotics
Intervention
Dothiepin
Comparator
Taper
Outcomes

PICO 50.5

Population
Patients using Benzodiazepines and closely related sedative hypnotics
Intervention
Ramelteon
Comparator
Taper
Outcomes